Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2015, Vol. 44 Issue (5): 500-505    DOI: 10.3785/j.issn.1008-9292.2015.09.05
专题报道     
洛伐他汀或辛伐他汀协同组蛋白去乙酰化酶抑制剂对人非小细胞肺癌的抑制作用
梁桂开1, 姚张婷1, 张洁琼1, 陈羲1, 刘瑞阳1, 陈卉卉1, 吴洪海1, 金露2, 丁玲1
1. 浙江大学药学院浙江省抗肿瘤药物临床前研究重点实验室, 浙江杭州 310058;
2. 温州医科大学附属第二医院神经内科, 浙江温州 325027
Statins enhance anti-tumor effect of suberoylanilide hydroxamic acid on human non-small cell lung carcinoma cells
LIANG Gui-kai1, YAO Zhang-ting1, ZHANG Jie-qiong1, CHEN Xi1, LIU Rui-yang1, CHEN Hui-hui1, WU Hong-hai1, JIN Lu2, DING Ling1
1. Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China;
2. Department of Neurology, the Second Affiliated Hospital Wenzhou Medical University, Wenzhou 325027, China
全文: PDF(837 KB)  
摘要: 

目的:研究他汀类药物能否协同增强组蛋白去乙酰化酶抑制剂辛二酰苯胺异羟肟酸(SAHA)对非小细胞肺癌A549细胞的生长抑制和凋亡诱导作用。方法:采用磺酰罗丹明B比色法检测不同浓度的SAHA与洛伐他汀/辛伐他汀合用对A549细胞存活率的影响;采用Annexin V/PI双染结合流式细胞术检测2.5μmol/L SAHA与不同浓度的洛伐他汀联合应用对A549细胞凋亡的影响;并采用蛋白质印迹法检测2.5μmol/L SAHA与5μmol/L洛伐他汀联合作用对凋亡相关标志蛋白聚腺苷二磷酸核糖聚合酶(c-PARP)及p21蛋白表达水平影响。结果:与SAHA组比较,洛伐他汀/辛伐他汀与SAHA合用组减少A549细胞的存活率。不同浓度的洛伐他汀能协同增加SAHA对A549细胞的凋亡诱导作用,同时合用组c-PARP的表达较单用两组增加,说明洛伐他汀能协同SAHA诱导A549细胞凋亡。2.5μmol/L SAHA单独作用A549细胞48 h可以上调A549细胞p21蛋白的表达,5μmol/L洛伐他汀与2.5μmol/L SAHA合用可以回调p21蛋白的表达。结论:洛伐他汀及辛伐他汀能增加SAHA对非小细胞肺癌A549细胞的生长抑制作用,其中洛伐他汀增强SAHA对A549细胞的生长抑制作用可能与其共同作用后p21蛋白表达下调相关。
关键词 ： 癌,非小细胞肺/药物疗法,  洛伐他汀/药理学,  辛伐他汀/药理学,  药物协同作用,  原癌基因蛋白质p21(ras)    
Abstract：

Objective:To evaluate the anti-tumor effect of the combination of suberoylanilide hydroxamic acid(SAHA) with statins(lovastatin or simvastatin) on non-small cell lung carcinoma(NSCLC) cells. Methods:Human NSCLC A549 cells were treated with SAHA in combination of lovastatin or simvastatin. The cell growth was analyzed by SRB method, and the apoptosis of A549 cells was assessed by flow cytometer. The expression of cleaved poly-ADP-ribose polymerase(cleaved-PARP) and p21 protein was analyzed by Western-blotting when A549 cells were challenged with 2.5μmol/L SAHA and 5μmol/L lovastatin. Results:Lovastatin and simvastatin synergized SAHA in the inhibition of A549 cells. SAHA induced apoptosis was also enhanced by lovastatin. Treatment with 2.5μmol/L SAHA significantly up-regulated the expression of p21 protein in 48 h, while the protein expression was reduced in combined treatment with 5μmol/L lovastatin. Conclusion:Statins can synergize the anti-tumor effect of SAHA in human NSCLC cells through a p21-dependent way.
Key words： Carcinoma, non-small-cell lung/drug therapy    Lovastatin/pharmacology    Simvastatin/pharmacology    Drug synergism    Proto-oncogene proteins p21(ras)
收稿日期: 2015-05-15
CLC:  R963  
基金资助:

浙江省自然科学基金(LY14H310008);浙江省教育厅科研项目(Y201226213)
通讯作者: 丁玲(1981-),女,博士,副教授,主要从事肿瘤药理学研究;E-mail:ld362@zju.edu.cn;金露(1978-),女,硕士,主治医师,主要从事神经病理学研究;E-mail:wzjinlu@126.com     E-mail: ld362@zju.edu.cn;wzjinlu@126.com
作者简介: 梁桂开(1991-),女,博士研究生,主要从事肿瘤药理学研究;Email:candylgk@zju.edu.cn;http://orcid.org/0000-0003-1681-5346
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

梁桂开等. 洛伐他汀或辛伐他汀协同组蛋白去乙酰化酶抑制剂对人非小细胞肺癌的抑制作用[J]. 浙江大学学报（医学版）, 2015, 44(5): 500-505.
LIANG Gui-kai, YAO Zhang-ting, ZHANG Jie-qiong, CHEN Xi, LIU Rui-yang, CHEN Hui-hui, WU Hong-hai, JIN Lu, DING Ling. Statins enhance anti-tumor effect of suberoylanilide hydroxamic acid on human non-small cell lung carcinoma cells. Journal of ZheJiang University(Medical Science), 2015, 44(5): 500-505.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2015.09.05      或      http://www.zjujournals.com/xueshu/med/CN/Y2015/V44/I5/500

[1] SCHAEFER E W, LOAIZA-BONILLA A, JUCKETT M, et al. A phase 2 study of vorinostat in acute myeloid leukemia[J]. Haematologica, 2009,94(10):1375-1382.
[2] BLUMENSCHEIN R, KIES S, PAPA DIMITRAKOPOULOU A, et al. Phase II trial of the histone deacetylase inhibitor vorinostat(zolinzatrade mark, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer[J]. Invest New Drugs, 2008,26(1):81-87.
[3] MODESITT S C, SILL M, HOFFMAN J S, et al. A phase Ⅱ study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2008,109(2):182-186.
[4] GALANIS E, JAECKLE K A, MAURER M J, et al. Phase Ⅱ trial of vorinostat in recurrent glioblastoma multiforme:a north central cancer treatment group study[J]. J Clin Oncol, 2009,27(12):3262-3263.
[5] MARCELLI M, CUNNINGHAM G R, HAIDACHER S J, et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP[J]. Cancer Res, 1998,58(1):76-83.
[6] SIDDIQUI R A, HARVEY K A, XU Z, et al. Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells[J]. Bioorg Med Chem, 2014,22(6):1899-1908.
[7] OSMAK M. Statins and cancer:current and future prospects[J]. Cancer Lett, 2012,324(1):1-12.
[8] SANLI T, LIU C, RASHID A, et al. Lovastatin sensitizes lung cancer cells to ionizing radiation:modulation of molecular pathways of radioresistance and tumor suppression[J]. J Thorac Oncol, 2011,6(3):439-450.
[9] YAZBECK V Y, BUGLIO D, GEORGAKIS G V, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma[J]. Exp Hematol, 2008,36(4):443-450.
[10] CAREW J S, MEDINA E C, ESQUIVEL II, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation[J]. J Cell Mol Med, 2010,14(10):2448-2459.
[11] ELLIS L, HAMMERS H, PILI R. Targeting tumor angiogenesis with histone deacetylase inhibitors[J]. Cancer Lett, 2009,280(2):145-153.
[12] MILDE T, KLEBER S, KORSHUNOV A, et al. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor vorinostat[J]. Acta Neuropathol, 2011,122(5):637-650.
[13] RAMALINGAM S S, PARISE R A, RAMANANTHAN R K, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies[J]. Clin Cancer Res, 2007,13(12):3605-3610.
[14] STINE J. The HMG-CoA reductase inhibitor, simvastatin, has anti-tumorigenic effects in ovarian cancer cell lines and a genetically engineered serous ovarian cancer mouse model[J]. Gynecol Oncol, 2015, 137:63-64.
[15] WANG T, SEAH S, CHAN C, et al. Simvastatin induced apoptosis and suppressed proliferation of breast cancer through deactivating PI3K/Akt/mTOR pathway[J]. Cancer Res, 2014,74(19 Suppl):2630.
[16] OWONIKOKO T K, RAMALINGAM S S, KANTEREWICZ B, et al. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells[J]. Int J Cancer, 2010,126(3):743-755.
[17] DOI T, HAMAGUCHI T, SHIRAO K, et al. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal(GI) cancer in a phase I clinical trial[J]. Int J Clin Oncol, 2013,18(1):87-95.
[18] XIA M, KNEZEVIC D, VASSILEV L T. p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation[J]. Oncogene, 2011,30(3):346-355.
[19] DE RENTY C, DEPAMPHILIS M L, ULLAH Z. Cytoplasmic localization of p21 protects trophoblast giant cells from DNA damage induced apoptosis[J]. PLoS One, 2014,9(5):e97434.
[1] 刘健翔，方吟荃，魏峥曦，杨幸巧，曾玲晖. 槲皮素与贯叶连翘提取物合用抗抑郁作用初步研究[J]. 浙江大学学报（医学版）, 2013, 42(6): 615-619.
[2] . 生脉方主要活性成分配伍对其药代动力学行为的影响[J]. 浙江大学学报（医学版）, 2012, 41(1): 6-12.
[3] 王洪燕;全康;蒋燕灵;吴加国;唐修文. 木犀草素抗肿瘤细胞增殖及增敏抗肿瘤药物作用研究[J]. 浙江大学学报（医学版）, 2010, 39(1): 30-36.
[4] 赵新汉;王志宇;李琳琳;李丽;李晓花. 三苯氧胺诱导乳腺癌细胞凋亡过程中ERα和SMRT的表达变化[J]. 浙江大学学报（医学版）, 2008, 37(3): 276-282.
[5] 夏大静, 鲍建芳, 沈建根, 邵传森. IL-12联合小剂量IL-2对人外周血单个核细胞增殖及杀瘤活性的影响[J]. 浙江大学学报（医学版）, 1999, 28(6): 248-252.
[6] 刘剑, 郑树, 冯懿正, 陈丽荣, 黄学峰, 耿礼义, 彭加萍. 家族性腺瘤性息肉病肠粘膜、腺瘤及癌组织的基因蛋白检测与意义[J]. 浙江大学学报（医学版）, 1998, 27(3): 101-104,107.
[7] 严清和, 陆莉莉. 法莫替丁联合西沙比利治疗反流性食管炎25例疗效观察[J]. 浙江大学学报（医学版）, 1996, 25(2): 72-73,75.